Inhibikase Therapeutics, Inc. (IKT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45719W2052
Inhibikase Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -51.97 m USD |
| EBIT | -48.26 m USD |
| Net income | -48.26 m USD |
| Diluted EPS – continuing operations | -0.49 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
More stocks
- TYC Brother Industrial Co Ltd (1522.TW)
- Bioteque (4107.TWO)
- 029 Group (Z29.DE)
- Dustin Group AB (DUST.ST)
- Volati AB (VOLO.ST)
- PRO DEX INC (PDEX)
- Starrag Group Holding AG (STGN.SW)
- SPC Samlip Co Ltd (005610.KS)
- SOUTH DAKOTA SOYBEAN PROCESSORS LLC (SDSYA)
- Shin Shin Natural Gas Co Ltd (9918.TW)
- RichWave Technology Corp (4968.TW)
- AC Immune Ltd (ACIU)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.